What is Atrantil PRO?

The Atrantil Pro formula is a combination of two clinically studied GI support supplements, balanced for optimal restoration and protection of digestive function.* This combination is the most studied comprehensive OTC option for health professionals.

Become an
Atrantil-PRO
Retailer See Clinical
Research
Results

The Atrantil Pro formula is a combination of two clinically studied GI support supplements, balanced for optimal restoration and protection of digestive function.* This combination is the most studied comprehensive OTC option for health professionals.

Digestive System

Atrantil Polyphenols

  • Methane
  • Harmful bacteria
  • NFKB
  • TNF-Alpha
  • Chronic inflammatory pathways
  • Hydrogen sulfide
  • Anti-oxidants
  • Anti-aging
  • SIRT1 pathway
  • NRF2 pathway
  • Short chain fatty acids (Butyrate, Propionate, etc)
  • Helpful bacteria, including
    Akkermansia muciniphila
  • Microbial diversity
Digestive System

Mega trio Spore Biotic

B subtilis, B coagulans, B clausii

  • Inflammatory markers (IL6)
  • Intestinal permeability (leaky gut)
  • LPS signaling
  • Harmful bacteria
  • NFKB
  • TNF-Alpha
  • Chronic inflammatory pathways
  • SCFA Butyrate
  • SCFA Propionate
  • Microbial Diversity
  • **Key for Antibiotic associated
  • Dysbiosis
  • Helpful bacteria, including
    Akkermansia muciniphila

Become an Atrantil PRO Retailer

If you’re ready to give your patients the latest in efficacy and safety for bloating and abdominal discomfort accompanied by constipation, diarrhea or both, the Atrantil team’s here to help.

Fill out this form or call 214-984-3724 ext. 708

RESULTS PROVEN IN CLINICAL RESEARCH

Dr. Kenneth Brown and his team created Atrantíl based on their understanding of how its three main natural botanicals would work together to relieve bloating, abdominal discomfort, and changes in bowel habits—constipation, diarrhea, or both. And to prove their formula was more than just a good idea, they tested it twice with real patients.

Double-Blind Study

A double-blind clinical trial evaluated Atrantil in patients experiencing bloating, constipation, and abdominal discomfort.

In this study:

  • 88% of patients experienced symptom improvement

Additional study details:

  • Randomized, double-blind study design
    Evaluated key gastrointestinal symptoms, including bloating and abdominal discomfort

The study was published in: Journal of Gastroenterology and Hepatology Research September 21, 2015

View Clinical Trial

Open-Label Study

An open-label clinical study evaluated Atrantil in patients with persistent digestive symptoms who had not responded to previous treatments.

In this study:

80% of patients reported symptom improvement

Additional study details:

Participants had previously failed multiple therapies

Evaluated real-world patients with ongoing symptoms

The study was published in: World Journal of Gastrointestinal Pharmacology and Therapeutics August 6, 2016

Additional study details:

The study was led by Darren Brenner, MD, FACG, AGAF

Conducted independently of KBS Research and its partners

View Clinical Trial

Northwestern University Feinberg School of Medicine Study

An independent study conducted at Northwestern University Feinberg School of Medicine evaluated Atrantil in patients experiencing gastrointestinal symptoms associated with methane-producing microbes.

In this study:

  • 56% of participants reported adequate symptom relief
  • Outcomes were measured across seven symptom categories
  • Participants were enrolled with minimal exclusion criteria to reflect real-world patients

Additional study details:

The study was led by Darren Brenner, MD, FACG, AGAF

Conducted independently of KBS Research and its partners

View Clinical Trial